Board of Directors
On October 1, 2014, Russell H. Plumb became Executive Chairmen, Director. Previously, Mr. Plumb served as President and Chief Executive Officer from November 2012 to September 2014.
Mr Plumb served as President, Chief Executive Officer and Chief Financial Officer of Inhibitex Inc., a US publicly-traded, clinical-stage drug development company, from December 2006 through February 2012, when it was acquired by Bristol-Myers Squibb for approximately $2.5 billion. Prior to its acquisition, Inhibitex focused its resources in recent years on developing antiviral, small molecules, including compounds to treat hepatitis C virus (HCV). From 2000 to December 2006, Mr Plumb was the Chief Financial Officer of Inhibitex, during which time he oversaw numerous financing transactions, including the company's initial public offering in 2004.
Mr Plumb has received designations as a certified public accountant in Michigan and Georgia. Mr Plumb received both a BComm and an MBA from the University of Toronto.
Ms. VanLent was appointed a Director of Biota Pharmaceuticals in May 2013.
Ms. VanLent is currently the President of AMV Advisors, an advisory firm which she founded in 2008 to provide corporate strategy and financial consulting services to emerging growth life science companies. Previously, Ms. VanLent was Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. Prior to that, she was Executive Vice President, Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. Earlier in her career, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc. Ms. VanLent also currently serves as a director and chairs the audit committees of Aegerion Pharmaceuticals, Inc., Ocera Pharmaceuticals, Inc., and Onconova Therapeutics, Inc. She previously served as a member of the Board of Directors of i-STAT Corporation, Integra LifeSciences and Penwest Pharmaceuticals.
Dr. Patti joined the Company on November 12, 2012 and served as its Executive Vice President of Corporate Development and Strategy until October 1, 2014, when he was appointed as the Company’s President and Chief Executive Officer. Prior to joining the Company, Dr. Patti co-founded Inhibitex, Inc. in 1998 and served as its Chief Scientific Officer and Senior Vice President of Research and Development from 2007 until it was acquired by Bristol Myers Squibb in February 2012. He also served as its Chief Scientific Officer and Vice President of Research and Development from 2005 to 2007 and as Vice President, Preclinical Development prior to that. Before co-founding Inhibitex in 1998, Dr. Patti was an Assistant Professor at Texas A&M's Institute of Biosciences and Technology and also served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. Dr. Patti is currently a director of SciStem Therapeutics, Inc., a privately-held company focused on developing cellular therapies for bone healing and musculoskeletal indications in both human and animal health. Dr. Patti was a director of Inhibitex from 1998 to 2005.
Dr. Patti received a B.S. in Microbiology from the University of Pittsburgh, an M.S.P.H. from the University of Miami, School of Medicine and a Ph.D. in Biochemistry from the University of Alabama at Birmingham.
Mr. Anido was appointed a Director of Biota Pharmaceuticals in October 2015.
Mr. Anido has served as Chairman of the Board and Chief Executive Officer of Zynerba Pharmaceuticals since October 2014. Prior to joining Zynerba, Mr. Anido served as Chief Executive Officer and director of NuPathe, Inc. from 2012 through its acquisition by Teva Pharmaceuticals in 2014, during which time he led the company through FDA approval of its lead product, Zecuity, a transdermal patch for migraine. From 2006 to 2011, Mr. Anido served as Chief Executive Officer and President and as a director of Auxilium Pharmaceuticals, Inc., a specialty pharmaceutical company acquired by Endo International plc. Prior to its acquisition by AstraZeneca, Mr. Anido served as Executive Vice President, Sales and Marketing at MedImmune, Inc. and played a major role in the commercial success of Synagis®, a monoclonal antibody for the prevention of respiratory syncytial infections in infants. Mr. Anido also served in a series of positions with increasing responsibility at Glaxo Wellcome, Inc, including Director, HIV Marketing and Vice President, Central Nervous System Marketing. He holds an M.B.A. and a B.S. in Pharmacy from West Virginia University.
Dr. Geoffrey F. Cox has been a Director since 2000.
Dr. Cox is a partner with Red Sky Partners LLC and a member of the board of directors of QLT Inc. Dr. Cox served as Chairman of the Board, President and Chief Executive Officer of GTC Biotherapeutics, Inc., a biopharmaceutical company, from 2001 to 2010. From 1997 to 2001, he was Chairman of the Board and Chief Executive Officer of Aronex Pharmaceuticals, Inc., a biotechnology company. From 1984 to 1997, he was employed by Genzyme Corporation, a biotechnology company, last serving as its Executive Vice President, Operations. Dr. Cox is Chairman of the Board of the Massachusetts Biotechnology Council (MassBio) and served for a number of years on the Board of the Biotechnology Industries Association (BIO), together with the Health Governing Sections and Emerging Companies Sections of BIO. Dr. Cox received a BSc in Biochemistry from the University of Birmingham, United Kingdom, and a PhD in Biochemistry from the University of East Anglia, United Kingdom.
Mr. Dougherty was appointed a Director of Biota Pharmaceuticals in May 2013.
Formely, Mr. Dougherty was Chief Executive Officer of Kalidex Pharmaceuticals, a privately-held, venture-backed infectious disease company. Prior to Kalidex, he served as Chief Executive Officer and a director of Adolor Corporation, a biopharmaceutical company acquired by Cubist Pharmaceuticals in 2011. He also served in other executive roles at Adolor before being appointed CEO, including Chief Operating Officer, Chief Financial Officer, and Senior Vice President, Commercial Operations. Prior to joining Adolor, he served in a number of executive roles, including Chief Operating Officer of Genomics Collaborative, Chief Executive Officer, Chief Financial Officer and a director of Genaera Corp, and Chief Financial Officer of Centocor, Inc. Mr. Dougherty currently serves on the Board and Chairs the Audit Committee of ViroPharma, Inc.
Dr. Dunne was appointed a Director of Biota Pharmaceuticals in October 2015.
Dr. Dunne is currently Chief Science Officer of Iterum Pharmaceuticals plc. From 2014-2015, Dr. Dunne was Vice President Research and Development at Actavis plc (now Allergan plc). Prior to its acquisition by Actavis plc in 2014, Dr. Dunne served as the Chief Medical Officer at Durata Therapeutics, during which time he led the clinical development of dalbavancin, an intravenous antibiotic for gram positive infections. Prior to joining Durata as Chief Medical Officer in 2009, Dr. Dunne worked at Pfizer for 17 years, which included holding positions of Vice President, Therapeutic Area Development and Head, Infectious Diseases, Global R&D and, subsequent to that, Vice President, Portfolio Policy, Worldwide Policy & Public Affairs, Global R&D. During his time at Pfizer, Dr. Dunne led the clinical development of a number of infectious diseases products, including maraviroc, voriconazole, and Zithromax®. Dr. Dunne currently sits on the scientific advisory committee for the Global Alliance for TB Drug Development and the Medicines for Malaria Venture. Dr. Dunne holds an M.D. from the State University of New York Health Science Center at Brooklyn, completed his residency in Internal Medicine as well as fellowships in pulmonary medicine and infectious diseases at Yale University and has a B.A. in Economics from Northwestern University.
Mr. Richard has served as a member of our Board of Directors since August 2013,
Mr. Richard is an operating partner and non-executive director for Phase4 Partners. He is also co-founder and Head of Corporate Development for Mereo BioPharma Ltd, a pharmaceutical spin-out launched by Phase4 Partners in 2015. From 2005 until 2015 Mr. Richard was also a partner with Georgia Venture Partners, a seed venture capital firm focused on the biotechnology industry. Earlier in his career he headed business development for the public companies SEQUUS Pharmaceuticals, VIVUS, and Genome Therapeutics, and was CEO and co-founder of Impath (subsequently acquired by Genzyme). Mr. Richard currently serves as a director of Catalyst Biosciences, Inc.
Mr. Richard received his M.B.A. from the Harvard Business School and a B.S. from Stanford University.